Trendlines Medical, K2 Global to jointly collaborate on Startup SG

Trendlines Medical Singapore, a subsidiary of SGX-listed Israeli firm The Trendlines Group, is partnering Ozi Amanat’s venture capital firm K2 Global to participate in SPRING SEEDS Capital’s (SSC) S$100 million investment allocation via the Startup SG Equity scheme.

As part of the Startup SG Equity scheme, the SSC supports early-stage startups across technology and industry domains and aims to catalyse private-sector investments in startups via government equity co-investment. It announced its S$100 million investment allocation in July 2017 and has appointed a number of co-investment partners across the health & biomedical sciences, financial technology and other fields.

Bring stories like this into your inbox every day.

Sign up for our newsletter - The Daily Brief
Subscribe to Newsletter